GlassScriptPhysician profile
Krishna Komanduri
NPI 1295093466
$4,010.18
in general payments reported to CMS, 2019-2025
29 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $231 · 2021: $340 · 2022: $179 · 2023: $48.83 · 2024: $769 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118 · Education: $64.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.03 |
| Education | $64.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $598.30 | 2019-2025 | Rayaldee |
| Amgen INC. | $449.95 | 2019-2025 | Tavneos, Krystexxa, Uplizna |
| Vifor Pharma, INC. | $311.87 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $296.80 | 2021-2025 | |
| Glaxosmithkline, LLC. | $211.30 | 2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $207.24 | 2021-2025 | Farxiga, Lokelma |
| Shionogi INC | $164.22 | 2019-2020 | |
| Travere Therapeutics, INC. | $159.16 | 2024-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $154.11 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $139.05 | 2019-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $129.98 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $124.95 | 2019 | |
| Fresenius USA Marketing, INC. | $112.70 | 2019-2025 | Velphoro, Velphoro |
| Lilly USA, LLC | $110.30 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $110.08 | 2024-2025 | Tarpeyo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $108.35 | 2019-2025 | Ultomiris |
| Bard Peripheral Vascular, INC. | $98.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $84.21 | 2025 | |
| Mallinckrodt Hospital Products INC. | $83.72 | 2024-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.26 | 2024-2025 | Jardiance |
| Daiichi Sankyo INC. | $52.52 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $49.76 | 2019 | |
| Aurinia Pharma U.S., INC. | $44.48 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.23 | 2019-2020 | |
| Nxstage Medical, INC. | $23.45 | 2021 | |
| Abbvie INC. | $21.02 | 2019 | |
| Baxter Healthcare | $19.86 | 2019 | |
| Concordia Pharmaceuticals INC. | $14.37 | 2019 | |
| Vivus LLC | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Komanduri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.